Open Access

SGLT2 inhibitors in practice (part 2): how do we implement new treatments in HFpEF?

Event: ESC Congress 2022
Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)
Session type: Satellite Symposium
Sponsored by Boehringer Ingelheim & Eli Lilly
Date: 27 August 2022
Time: 12:45 - 13:45

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

4 presentations in this session

Introduction and recap.

Speaker: Professor S. Anker (Berlin, DE)
Thumbnail

What is the evidence for empagliflozin in HFpEF?

Speaker: Professor G. Rosano (London, GB)
Thumbnail

Implementing empagliflozin for HFpEF treatment in my practice.

Speaker: Professor M. Boehm (Homburg, DE)
Thumbnail

Panel discussion.

Speaker: Professor S. Anker (Berlin, DE)
Thumbnail

4 speakers from this session

Professor Stefan Anker

Charite Universitatsmedizin Berlin, Berlin (Germany)
116 presentations
4 followers

Professor Giuseppe M C Rosano

St Georges Medical School, London (United Kingdom of Great Britain & Northern Ireland)
64 presentations
13 followers

Professor Michael Boehm

Saarland University Hospital, Homburg (Germany)
58 presentations
0 follower

Professor Stefan Anker

Charite Universitatsmedizin Berlin, Berlin (Germany)
116 presentations
4 followers

This platform is supported by

logo Novo Nordisk